IMVT (Immunovant) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Immunovant's net issuance of preferred for the three months ended in Sep. 2024 was $0.00 Mil. The number is 0, which means that Immunovant has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Immunovant's net issuance of preferred for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Immunovant Net Issuance of Preferred Stock Historical Data

The historical data trend for Immunovant's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Net Issuance of Preferred Stock Chart

Immunovant Annual Data

Trend

Dec18

Mar20

Mar21

Mar22

Mar23

Mar24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Immunovant Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Immunovant Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Immunovant Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Immunovant's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William L. Macias	officer: Chief Medical Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett	officer: Chief Financial Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Mark S. Levine	officer: Chief Legal Officer	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jay S Stout	officer: Chief Technology Officer	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain	officer: Chief Medical Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018